Life Sciences Series: Regulatory risks in China

The Chinese government has intensified its anti-corruption campaign in the healthcare sector, introducing its first official compliance guidelines to mitigate bribery risks.

Join host Martina Rozumberkova for a discussion with Principal Regina Zhou about the evolving regulatory environment and the challenges of operating in China. They explore key lessons from high-profile investigations, the strategic importance of robust compliance frameworks, and recent regulatory reforms, like data transfer regulations and foreign investment in medical innovations — as well as new opportunities, despite the complexities of the landscape.

Find out more.